Fluconazole assists berberine to kill fluconazole-resistant Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6016-6027

  Li, De Dong ^a,b   Xu, Yi ^a,c   Zhang, Da Zhi ^a   Quan, Hua ^a,d   Mylonakis, Eleftherios ^b   Hu, Dan Dan ^a   Li, Ming Bang ^a   Zhao, Lan Xue ^a   Zhu, Liang Hua ^a   Wang, Yan ^a   Jiang, Yuan Ying ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b BROWN UNIVERSITY   (United States)

^c JINAN MILITARY GENERAL HOSPITAL   (China)

^d Shanghai Institute of Food and Drug Controls   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE ORANGE; ANTIFUNGAL AGENT; BERBERINE; FLUCONAZOLE; METHYLENE BLUE; SANGUINARINE; BENZOPHENANTHRIDINE DERIVATIVE; CARRIER PROTEIN; CELL CYCLE PROTEIN; FUNGAL PROTEIN; INTERCALATING AGENT; ISOQUINOLINE DERIVATIVE;

ARTICLE; CANDIDA ALBICANS; CELL CYCLE ARREST; CELL MEMBRANE; FLUCONAZOLE RESISTANT CANDIDA ALBICANS; FLUORESCENCE; FUNGAL CELL; GENE; MEASUREMENT; MEMBRANE; NONHUMAN; PRIORITY JOURNAL; ANTIFUNGAL RESISTANCE; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; TRANSPORT AT THE CELLULAR LEVEL;

ACRIDINE ORANGE; ANTIFUNGAL AGENTS; BENZOPHENANTHRIDINES; BERBERINE; BIOLOGICAL TRANSPORT; CANDIDA ALBICANS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; INTERCALATING AGENTS; ISOQUINOLINES; MEMBRANE TRANSPORT PROTEINS; METHYLENE BLUE; MICROBIAL SENSITIVITY TESTS;

EID: 84887422777     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00499-13     Document Type: Article

References (52)

1. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177.
2. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. 2002. The direct cost and incidence of systemic fungal infections. Value Health 5:26-34.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
4. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
5. Kohli A, Smriti Mukhopadhyay K, Rattan A, Prasad R. 2002. In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrob. Agents Chemother. 46:1046-1052.
6. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 46:1704-1713.
7. White TC, Marr KA, Bowden RA. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
8. Angiolella L, Stringaro AR, De Bernardis F, Posteraro B, Bonito M, Toccacieli L, Torosantucci A, Colone M, Sanguinetti M, Cassone A, Palamara AT. 2008. Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans. Antimicrob. Agents Chemother. 52:927-936.
9. Wilkerson J, McPherson C, Donze A. 2010. Fluconazole to prevent systemic fungal infections in infants: reviewing the evidence. Neonatal Netw. 29:323-333.
10. Niimi M, Firth NA, Cannon RD. 2010. Antifungal drug resistance of oral fungi. Odontology 98:15-25.
11. Gullo A. 2009. Invasive fungal infections: the challenge continues. Drugs 69(Suppl 1):65-73.
12. Wei GX, Xu X, Wu CD. 2011. In vitro synergism between berberine and miconazole against planktonic and biofilm Candida cultures. Arch. Oral Biol. 56:565-572.
13. Kamysz E, Simonetti O, Cirioni O, Arzeni D, Ganzetti G, Campanati A, Giacometti A, Gabrielli E, Silvestri C, Kamysz W, Offidani A, Barchiesi F. 2011. In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinical isolates of Candida spp. Peptides 32:99-103.
14. Kiraz N, Dag I, Yamac M, Kiremitci A, Kasifoglu N, Oz Y. 2010. Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods. Antimicrob. Agents Chemother. 54:2244-2247.
15. Karwa R, Wargo KA. 2009. Efungumab: a novel agent in the treatment of invasive candidiasis. Ann. Pharmacother. 43:1818-1823.
16. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. 2009. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J. Ethnopharmacol. 126:5-17.
17. Quan H, Cao YY, Xu Z, Zhao JX, Gao PH, Qin XF, Jiang YY. 2006. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole. Antimicrob. Agents Chemother. 50:1096-1099.
18. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1. doi:10.1093/jac/dkg301.
19. Xu Y, Wang Y, Yan L, Liang RM, Dai BD, Tang RJ, Gao PH, Jiang YY. 2009. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation. J. Proteome Res. 8:5296-5304.
20. Liang RM, Yong XL, Jiang YP, Tan YH, Dai BD, Wang SH, Hu TT, Chen X, Li N, Dong ZH, Huang XC, Chen J, Cao YB, Jiang YY. 2011. 2-amino-nonyl-6-methoxyl- tetralin muriate activity against Candida albicans augments endogenous reactive oxygen species production - a microarray analysis study. FEBS J. 278:1075-1085.
21. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, vol 28, no. 14. Approved standard - third edition; CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
22. de la Fuente-Salcido N, Salcedo-Hernandez R, Alanis-Guzman MG, Bideshi DK, Barboza-Corona JE. 2007. A new rapid fluorogenic method for measuring bacteriocin activity. J. Microbiol. Methods 70:196-199.
23. Pereira GC, Branco AF, Matos JA, Pereira SL, Parke D, Perkins EL, Serafim TL, Sardao VA, Santos MS, Moreno AJ, Holy J, Oliveira PJ. 2007. Mitochondrially targeted effects of berberine [Natural Yellow 18, 5,6-dihydro-9,10- dimethoxybenzo (g)-1,3-benzodioxolo(5,6-a) quinolizinium] on K1735-M2 mouse melanoma cells: comparison with direct effects on isolated mitochondrial fractions. J. Pharmacol. Exp. Ther. 323: 636-649.
24. Sinha R, Islam MM, Bhadra K, Kumar GS, Banerjee A, Maiti M. 2006. The binding of DNA intercalating and non-intercalating compounds to A-form and protonated form of poly(rC)·poly(rG): spectroscopic and viscometric study. Bioorg. Med. Chem. 14:800-814.
25. Teichert MC, Jones JW, Usacheva MN, Biel MA. 2002. Treatment of oral candidiasis with methylene blue-mediated photodynamic therapy in an immunodeficient murine model. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 93:155-160.
26. Giuliana G, Pizzo G, Milici ME, Musotto GC, Giangreco R. 1997. In vitro antifungal properties of mouthrinses containing antimicrobial agents. J. Periodontol. 68:729-733.
27. Oliver G, de Ruiz Holgado AP, Salim R. 1982. Dimorphism in Candida albicans, effect of cycloheximide and acridine orange on germ-tube formation. Mycopathologia 79:43-47.
28. Garcia-Effron G, Park S, Perlin DS. 2011. Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob. Agents Chemother. 55:2245-2255.
29. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. 2000. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5=-methoxyhydnocarpin, a multidrug pump inhibitor. Proc. Natl. Acad. Sci. U. S. A. 97:1433-1437.
30. Sanglard D, Ischer F, Monod M, Bille J. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143(Part 2):405-416.
31. MacCallum DM, Coste A, Ischer F, Jacobsen MD, Odds FC, Sanglard D. 2010. Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. Antimicrob. Agents Chemother. 54:1476-1483.
32. Vuddanda PR, Chakraborty S, Singh S. 2010. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin. Investig. Drugs 19:1297-1307.
33. Wu M, Wang J, Liu LT. 2010. Advance of studies on anti-atherosclerosis mechanism of berberine. Chin. J. Integr. Med. 16:188-192.
34. Chou HC, Lu YC, Cheng CS, Chen YW, Lyu PC, Lin CW, Timms JF, Chan HL. 2012. Proteomic and redox-proteomic analysis of berberineinduced cytotoxicity in breast cancer cells. J. Proteomics 75:3158-3176.
35. Boberek JM, Stach J, Good L. 2010. Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS One 5:e13745. doi:10 .1371/journal.pone.0013745.
36. Bhadra K, Kumar GS. 2011. Therapeutic potential of nucleic acidbinding isoquinoline alkaloids: binding aspects and implications for drug design. Med. Res. Rev. 31:821-862.
37. Yadav RC, Kumar GS, Bhadra K, Giri P, Sinha R, Pal S, Maiti M. 2005. Berberine, a strong polyriboadenylic acid binding plant alkaloid: spectroscopic, viscometric, and thermodynamic study. Bioorg. Med. Chem. 13: 165-174.
38. Novick P, Osmond BC, Botstein D. 1989. Suppressors of yeast actin mutations. Genetics 121:659-674.
39. Cairns BR, Lorch Y, Li Y, Zhang M, Lacomis L, Erdjument-Bromage H, Tempst P, Du J, Laurent B, Kornberg RD. 1996. RSC, an essential, abundant chromatin-remodeling complex. Cell 87:1249-1260.
40. Neely KE, Workman JL. 2002. The complexity of chromatin remodeling and its links to cancer. Biochim. Biophys. Acta 1603:19-29.
41. Lenaz G, Genova ML. 2007. Kinetics of integrated electron transfer in the mitochondrial respiratory chain: random collisions vs. solid state electron channeling. Am. J. Physiol. Cell Physiol. 292:C1221-C1239. doi:10.1152/ajpcell. 00263.2006.
42. Swoboda RK, Bertram G, Delbruck S, Ernst JF, Gow NA, Gooday GW, Brown AJ. 1994. Fluctuations in glycolytic mRNA levels during morphogenesis in Candida albicans reflect underlying changes in growth and are not a response to cellular dimorphism. Mol. Microbiol. 13:663-672.
43. Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY. 2002. The involvement of P-glycoprotein in berberine absorption. Pharmacol. Toxicol. 91:193- 197.
44. Ettefagh KA, Burns JT, Junio HA, Kaatz GW, Cech NB. 2011. Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition. Planta Med. 77:835-840.
45. Ball AR, Casadei G, Samosorn S, Bremner JB, Ausubel FM, Moy TI, Lewis K. 2006. Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial. ACS Chem. Biol. 1:594-600.
46. Samosorn S, Tanwirat B, Muhamad N, Casadei G, Tomkiewicz D, Lewis K, Suksamrarn A, Prammananan T, Gornall KC, Beck JL, Bremner JB. 2009. Antibacterial activity of berberine-NorA pump inhibitor hybrids with a methylene ether linking group. Bioorg. Med. Chem. 17: 3866-3872.
47. Carrillo-Muñoz AJ, Giusiano G, Ezkurra PA, Quindos G. 2006. Antifungal agents: mode of action in yeast cells. Rev. Esp. Quimioter. 19:130- 139.
48. Iwazaki RS, Endo EH, Ueda-Nakamura T, Nakamura CV, Garcia LB, Filho BP. 2010. In vitro antifungal activity of the berberine and its synergism with fluconazole. Antonie Van Leeuwenhoek 97:201-205.
49. Amin AH, Subbaiah TV, Abbasi KM. 1969. Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Can. J. Microbiol. 15:1067- 1076.
50. Hsieh PC, Siegel SA, Rogers B, Davis D, Lewis K. 1998. Bacteria lacking a multidrug pump: a sensitive tool for drug discovery. Proc. Natl. Acad. Sci. U. S. A. 95:6602-6606.
51. Borges-Walmsley MI, Walmsley AR. 2001. The structure and function of drug pumps. Trends Microbiol. 9:71-79.
52. Kheir MM, Wang Y, Hua L, Hu J, Li L, Lei F, Du L. 2010. Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem. Toxicol. 48:1105-1110.